Loading...
XNYS
AXP
Market cap192bUSD
Apr 02, Last price  
275.25USD
1D
1.76%
1Q
-7.77%
Jan 2017
271.56%
Name

American Express Co

Chart & Performance

D1W1MN
P/E
19.05
P/S
3.83
EPS
14.45
Div Yield, %
0.98%
Shrs. gr., 5y
-3.10%
Rev. gr., 5y
2.96%
Revenues
50.41b
-16.50%
23,347,000,00025,900,000,00027,731,000,00028,365,000,00024,523,000,00027,819,000,00029,962,000,00031,582,000,00032,974,000,00034,292,000,00032,818,000,00032,119,000,00033,471,000,00040,338,000,00043,556,000,00036,087,000,00042,380,000,00052,862,000,00060,363,000,00050,406,000,000
Net income
10.13b
+20.96%
3,734,000,0003,707,000,0004,012,000,0002,699,000,0002,130,000,0004,057,000,0004,935,000,0004,482,000,0005,359,000,0005,885,000,0005,163,000,0005,408,000,0002,736,000,0006,921,000,0006,759,000,0003,135,000,0008,060,000,0007,514,000,0008,374,000,00010,129,000,000
CFO
14.05b
-24.30%
8,045,000,0009,005,000,0008,484,000,0008,666,000,0006,384,000,0009,288,000,00010,475,000,0007,082,000,0008,547,000,00010,990,000,00010,972,000,0008,224,000,00013,540,000,0008,930,000,00013,632,000,0005,591,000,00014,645,000,00021,079,000,00018,559,000,00014,050,000,000
Dividend
Oct 04, 20240.7 USD/sh
Earnings
Apr 17, 2025

Profile

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
URL
https://www.americanexpress.com/
IPO date
May 18, 1977
Employees
77,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
50,406,000
-16.50%
60,363,000
14.19%
52,862,000
24.73%
Cost of revenue
22,436,000
39,131,000
32,824,000
Unusual Expense (Income)
NOPBT
27,970,000
21,232,000
20,038,000
NOPBT Margin
55.49%
35.17%
37.91%
Operating Taxes
2,766,000
2,139,000
2,071,000
Tax Rate
9.89%
10.07%
10.34%
NOPAT
25,204,000
19,093,000
17,967,000
Net income
10,129,000
20.96%
8,374,000
11.45%
7,514,000
-6.77%
Dividends
(1,999,000)
(1,780,000)
(1,565,000)
Dividend yield
0.95%
1.29%
1.41%
Proceeds from repurchase of equity
(5,920,000)
(3,622,000)
(3,446,000)
BB yield
2.81%
2.63%
3.10%
Debt
Debt current
1,374,000
1,293,000
1,000,000
Long-term debt
47,866,000
43,003,000
Deferred revenue
3,027,000
Other long-term liabilities
86,526,000
(47,866,000)
156,066,000
Net debt
(76,493,000)
(36,915,000)
929,000
Cash flow
Cash from operating activities
14,050,000
18,559,000
21,079,000
CAPEX
(1,563,000)
(1,855,000)
Cash from investing activities
(24,402,000)
(24,433,000)
(33,689,000)
Cash from financing activities
4,436,000
18,379,000
24,509,000
FCF
102,580,000
(43,635,000)
17,740,000
Balance
Cash
77,867,000
86,074,000
38,074,000
Long term investments
5,000,000
Excess cash
75,346,700
83,055,850
40,430,900
Stockholders' equity
18,894,000
16,685,000
39,822,000
Invested Capital
99,270,000
245,716,000
172,496,000
ROIC
14.61%
9.13%
11.08%
ROCE
23.67%
8.09%
9.37%
EV
Common stock shares outstanding
709,000
736,000
752,000
Price
296.79
58.42%
187.34
26.80%
147.75
-9.69%
Market cap
210,424,110
52.61%
137,882,240
24.10%
111,108,000
-14.03%
EV
133,931,110
100,967,240
138,641,000
EBITDA
29,646,000
22,883,000
21,664,000
EV/EBITDA
4.52
4.41
6.40
Interest
8,252,000
6,849,000
2,763,000
Interest/NOPBT
29.50%
32.26%
13.79%